Immunotherapy of chronic lymphocytic leukemia

William G. Wierda; Susan O'Brien

doi:10.1586/14737140.1.1.73

Immunotherapy of chronic lymphocytic leukemia

William G. Wierda, Susan O'Brien

Leukemia

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available. Immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of this disease. This review discusses the different modalities of immunotherapy under investigation for the treatment of CLL. These modalities include passive immunotherapy with monoclonal antibodies against antigens on CLL B-cells including CD52 and CD20. Active immunotherapy by vaccination with genetically modified autologous leukemia cells is being evaluated in clinical trials. Allogeneic stem cell transplant for adoptive immunotherapy of CLL is yet another modality being investigated. While this modality may have limited application due to morbidity in older patients, it may result in improved survival and possibly cure. The use of immunotherapy in CLL is in the early stages of development. It is likely that this approach will significantly improve the treatment of CLL and possibly contribute to the cure of this disease.

Original language	English (US)
Pages (from-to)	73-83
Number of pages	11
Journal	Expert review of anticancer therapy
Volume	1
Issue number	1
DOIs	https://doi.org/10.1586/14737140.1.1.73
State	Published - 2001

Keywords

Allogeneic
CD154
CD40-ligand
Campath-1H
Chronic lymphocytic leukemia
Gene therapy
IL-2
Immunotherapy
Monoclonal antibody
Rituxan
Rituximab
Stem cell transplantation

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/14737140.1.1.73

Cite this

@article{7491864314ea43dbb4be45f047acd5f2,

title = "Immunotherapy of chronic lymphocytic leukemia",

abstract = "Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available. Immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of this disease. This review discusses the different modalities of immunotherapy under investigation for the treatment of CLL. These modalities include passive immunotherapy with monoclonal antibodies against antigens on CLL B-cells including CD52 and CD20. Active immunotherapy by vaccination with genetically modified autologous leukemia cells is being evaluated in clinical trials. Allogeneic stem cell transplant for adoptive immunotherapy of CLL is yet another modality being investigated. While this modality may have limited application due to morbidity in older patients, it may result in improved survival and possibly cure. The use of immunotherapy in CLL is in the early stages of development. It is likely that this approach will significantly improve the treatment of CLL and possibly contribute to the cure of this disease.",

keywords = "Allogeneic, CD154, CD40-ligand, Campath-1H, Chronic lymphocytic leukemia, Gene therapy, IL-2, Immunotherapy, Monoclonal antibody, Rituxan, Rituximab, Stem cell transplantation",

author = "Wierda, {William G.} and Susan O'Brien",

note = "Funding Information: Numerous information resources are currently available through the internet and are continuously becoming available. The most recently published peer-reviewed articles can be found by searching the National Library of Medicine database at the following address: www.ncbi.nlm.nih.gov/entrez. The American Society of Hematology website provides information regarding annual meetings and resources at the following address: www.hematology.org. The National Cancer Institute has recently funded the CLL Research Consortium which is a multi-institutional organization for CLL research and clinical trials and which maintains a website at the following address: www.cll.ucsd.edu. A patient advocate group maintains an extensive website with CLL disease-related links at the following address: www.acor.org/leukemia/cll.html. Information regarding clinical trials can be found at the following websites: www.cancernet.nci.nih.gov and cancertrials.nci.nih.gov.",

year = "2001",

doi = "10.1586/14737140.1.1.73",

language = "English (US)",

volume = "1",

pages = "73--83",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "1",

}

TY - JOUR

T1 - Immunotherapy of chronic lymphocytic leukemia

AU - Wierda, William G.

AU - O'Brien, Susan

N1 - Funding Information: Numerous information resources are currently available through the internet and are continuously becoming available. The most recently published peer-reviewed articles can be found by searching the National Library of Medicine database at the following address: www.ncbi.nlm.nih.gov/entrez. The American Society of Hematology website provides information regarding annual meetings and resources at the following address: www.hematology.org. The National Cancer Institute has recently funded the CLL Research Consortium which is a multi-institutional organization for CLL research and clinical trials and which maintains a website at the following address: www.cll.ucsd.edu. A patient advocate group maintains an extensive website with CLL disease-related links at the following address: www.acor.org/leukemia/cll.html. Information regarding clinical trials can be found at the following websites: www.cancernet.nci.nih.gov and cancertrials.nci.nih.gov.

PY - 2001

Y1 - 2001

N2 - Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available. Immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of this disease. This review discusses the different modalities of immunotherapy under investigation for the treatment of CLL. These modalities include passive immunotherapy with monoclonal antibodies against antigens on CLL B-cells including CD52 and CD20. Active immunotherapy by vaccination with genetically modified autologous leukemia cells is being evaluated in clinical trials. Allogeneic stem cell transplant for adoptive immunotherapy of CLL is yet another modality being investigated. While this modality may have limited application due to morbidity in older patients, it may result in improved survival and possibly cure. The use of immunotherapy in CLL is in the early stages of development. It is likely that this approach will significantly improve the treatment of CLL and possibly contribute to the cure of this disease.

AB - Chronic lymphocytic leukemia (CLL) is typically an indolent B-cell malignancy, primarily affecting the aging population. Standard cytotoxic treatment with alkylating agents or purine analogs is very effective at inducing remission. However, curative treatment is not yet available. Immunotherapy is emerging as an exciting modality with significant potential to advance the treatment of this disease. This review discusses the different modalities of immunotherapy under investigation for the treatment of CLL. These modalities include passive immunotherapy with monoclonal antibodies against antigens on CLL B-cells including CD52 and CD20. Active immunotherapy by vaccination with genetically modified autologous leukemia cells is being evaluated in clinical trials. Allogeneic stem cell transplant for adoptive immunotherapy of CLL is yet another modality being investigated. While this modality may have limited application due to morbidity in older patients, it may result in improved survival and possibly cure. The use of immunotherapy in CLL is in the early stages of development. It is likely that this approach will significantly improve the treatment of CLL and possibly contribute to the cure of this disease.

KW - Allogeneic

KW - CD154

KW - CD40-ligand

KW - Campath-1H

KW - Chronic lymphocytic leukemia

KW - Gene therapy

KW - IL-2

KW - Immunotherapy

KW - Monoclonal antibody

KW - Rituxan

KW - Rituximab

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0035559714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035559714&partnerID=8YFLogxK

U2 - 10.1586/14737140.1.1.73

DO - 10.1586/14737140.1.1.73

M3 - Review article

C2 - 12113136

AN - SCOPUS:0035559714

SN - 1473-7140

VL - 1

SP - 73

EP - 83

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 1

ER -

Immunotherapy of chronic lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this